Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Genmab ( (GMAB) ) has shared an update.
On May 20, 2025, Genmab A/S announced a capital increase resulting from the exercise of employee warrants, leading to the issuance of 1,746 new shares. This increase, which does not grant preemption rights to existing shareholders, is expected to raise approximately DKK 1.7 million and represents about 0.003% of Genmab’s total share capital. The new shares will be listed on Nasdaq Copenhagen, enhancing the company’s financial flexibility and potentially impacting its market positioning.
The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab exhibits strong financial performance with consistent profitability and low leverage. The company’s robust pipeline and strategic investments support future growth. However, technical analysis indicates neutral momentum, and dependency on key products introduces some risk.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. Genmab aims to transform the lives of people with cancer and other serious diseases by 2030.
Average Trading Volume: 1,500,837
Technical Sentiment Signal: Sell
Current Market Cap: $12.23B
For an in-depth examination of GMAB stock, go to TipRanks’ Stock Analysis page.